Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III double-blind comparative study of NE-58095 once-monthly formulation in osteoporosis
jRCT2080220994Phase 3
- Sponsor
- Ajinomoto
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of risedronate in osteoporosis (2 arms), sponsored by Ajinomoto.
02
Drugs
risedronate
03
Conditions
osteoporosis
Beyond the preview
Go deeper on jRCT2080220994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220994.